Compare Conagra Brands Inc (CAG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs TG Therapeutics Inc — how do they compare? Conagra Brands Inc trades at $14.95 (market cap $7.14B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Conagra Brands Inc and TG Therapeutics Inc are close in size by market cap, and Conagra Brands Inc pays a 8.2% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CAG | TGTX | |
|---|---|---|
Market Cap | $7.14B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $59.06 |
52-Week Low | $12.58 | $26.94 |
Enterprise Value | $14.20B | $7.84B |
Dividend Yield | 8.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $15.06, up 1.89% with mixed technical signals showing neutral overall momentum. The company faces fundamental challenges with negative net income margin (-16.99%) and ROE (-25.06%) despite recent earnings beats. Recent developments include a 50% dividend cut to $0.18, new executive appointments, and strategic shifts under CEO John Brase to address margin pressure and declining sales.
While CAG's low valuation (P/E 10.06, P/S 0.63) offers potential upside, persistent revenue declines and margin compression present significant headwinds. Analyst consensus remains cautious with 62.5% hold ratings, though the company's debt reduction efforts and operational simplification could support a turnaround if execution improves.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
